Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
详细信息 查看全文
- 作者：Alexi A. Wrighta ; 1 ; Kari Bohlkeb ; Deborah K. Armstrongc ; Michael A. Bookmand ; William A. Clibye ; Robert L. Colemanf ; Don S. Dizong ; Joseph J. Kashh ; Larissa A. Meyeri ; Kathleen N. Moorej ; Alexander B. Olawaiyek ; Jessica Oldhaml ; Ritu Salanim ; Dee Sparacion ; William P. Tewo ; Ignace Vergotep ; Mitchell I. Edelsonq ; 1 ; Mitchell.Edelson@jefferson.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Neoadjuvant ; Chemotherapy ; Ovarian cancer ; Cytoreductive surgery ; Guideline
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：143
- 期：1
- 页码：3-15
- 全文大小：652 K
文摘
- •
Women with high perioperative risks or low likelihood of achieving cytoreduction < 1 cm (ideally no visible disease) should receive NACT.
- •
NACT is non-inferior to PCS for progression-free and overall survival and has lower peri- and postoperative morbidity and mortality.
- •
However, primary cytoreductive surgery may offer superior survival in selected patients.